Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) jumped 6.88% in pre-market trading on Monday following the release of its better-than-expected first-quarter 2025 financial results. The biopharmaceutical company, known for its lupus nephritis treatment LUPKYNIS, reported earnings that surpassed analyst estimates and reaffirmed its full-year guidance.

Aurinia announced earnings per share of $0.16 for Q1 2025, significantly beating the analyst consensus estimate of $0.10. This represents a remarkable turnaround from the $0.07 loss per share reported in the same quarter last year. The company's revenue also impressed, coming in at $62.5 million, up 24% year-over-year and surpassing the analyst expectations of $61.54 million.

The strong performance was primarily driven by increased sales of LUPKYNIS, which reached $60.0 million in the quarter, up 25% from the previous year. Aurinia's President and CEO, Peter Greenleaf, expressed satisfaction with the company's momentum, citing the recent update to the American College of Rheumatology lupus nephritis treatment guideline as a potential catalyst for further growth. Additionally, the company reiterated its full-year 2025 total revenue guidance of $250 million to $260 million, instilling confidence in investors about its continued growth trajectory.